SCHEMBL9924067

SCHEMBL9924067

CCOC(=O)N[C@H]1CC[C@H](N/C(=N\C(=O)c2ccc(F)c(F)c2)NCc2ccc(Cl)c(F)c2)CC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.43
TSHR P16473 2/20 0.43
SSTR3 P32745 1/20 0.41
CHRM1 P11229 1/20 0.39
LMNA P02545 3/20 0.38
PPARG P37231 1/20 0.37
ALDH1A1 P00352 2/20 0.36
HTT P42858 1/20 0.36
S1PR3 Q99500 1/20 0.35
ROCK2 O75116 1/20 0.35
ROCK1 Q13464 1/20 0.35
MCHR1 Q99705 1/20 0.35
POLB P06746 1/20 0.35
WDR5 P61964 1/20 0.35
CYP2C9 P11712 1/20 0.35
MAPK14 Q16539 1/20 0.35
P2RX7 Q99572 1/20 0.35
PDE4D Q08499 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9923856 0.95 CHRM1 (0.42) SMN1; SMN2TSHRSSTR3CHRM1LMNA
SCHEMBL9924063 0.94 SMN1; SMN2 (0.43) SMN1; SMN2TSHRSSTR3CHRM1LMNA
SCHEMBL9924273 0.92 CHRM1 (0.41) SMN1; SMN2TSHRSSTR3CHRM1LMNA
SCHEMBL9924267 0.90 SMN1; SMN2 (0.47) SMN1; SMN2TSHRSSTR3CHRM1LMNA
SCHEMBL9924066 0.88 CHRM1 (0.41) SMN1; SMN2TSHRCHRM1LMNAALDH1A1
SCHEMBL9924269 0.87 SSTR3 (0.45) SSTR3PPARGALDH1A1MCHR1CYP2C9
SCHEMBL9923857 0.87 LMNA (0.40) SMN1; SMN2CHRM1LMNAHTTS1PR3
SCHEMBL9924276 0.86 EPHX2 (0.42) SMN1; SMN2TSHRCHRM1LMNAPPARG
SCHEMBL9924270 0.86 HPGD (0.40) SMN1; SMN2CHRM1LMNAALDH1A1MCHR1
SCHEMBL9924065 0.85 P2RX7 (0.42) P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9169199-B2 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-10-27 US disclosed
WO-2012078867-A2 CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORPORATION (US) 2012-06-14 WO disclosed